Liye Pharmaceutical

Liye Pharmaceutical is a prominent Chinese pharmaceutical enterprise focused on the development, production, and commercialization of respiratory, cardiovascular, and anti-infective medications. The company is particularly recognized for its expertise in inhalation drug delivery systems, including metered-dose inhalers (MDIs) and dry powder inhalers (DPIs). Operating under the broader Liye Group, the company maintains large-scale GMP-certified manufacturing bases in Shenzhen and Hangzhou. Its product portfolio includes widely used treatments for asthma and COPD, such as salbutamol and ipratropium formulations. Liye Pharmaceutical continues to invest in R&D to transition from high-quality generics to innovative drug development. The company serves a significant portion of the Chinese domestic market and is increasingly looking toward international expansion.